Celldex Q4 net loss $26.5M ($0.56/sh); barzolvolimab Phase 2 CSU enrollment to complete by Q3 2023

Celldex Therapeutics, Inc.

2022-FY EPS reported -$2.40 revenue$2,357,000

Net loss of $26.5M ($0.56 per share) for Q4 2022; full year net loss $112.3M ($2.40 per share).
Cash, cash equivalents and marketable securities at Dec 31, 2022: $305.0M, down from $323.5M at Sep 30, 2022.
Revenue $1.6M in Q4 2022, $2.4M for full year; R&D expenses $22.9M in Q4, $82.3M for full year.
Barzolvolimab Phase 2 CSU enrollment expected to complete by Q3 2023; topline data late 2023 or Q1 2024.
Rita Jain, M.D. appointed to Board of Directors; Phase 2 EoE study initiation expected H1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Celldex Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.

Period: the fourth quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2022

View on SEC.gov

Browse all earnings releases →

Celldex Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-23-001254

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.